Metformin is not known to cause breast enlargement. It is not listed as a side effect on the FDA label, and no clinical studies have linked metformin use to increases in breast size or breast tissue volume. In fact, the available evidence points in the opposite direction: metformin tends to lower estrogen levels and reduce the local production of estrogen within breast tissue, which would work against breast growth rather than promote it.
What the FDA Label Actually Lists
The official FDA prescribing information for metformin lists only three adverse reactions occurring in more than 5% of patients: low blood sugar, diarrhea, and nausea. Breast-related changes of any kind, including enlargement, tenderness, or swelling, do not appear anywhere in the adverse reaction tables. This is significant because the FDA label captures side effects reported across large clinical trials involving hundreds of patients.
How Metformin Affects Hormones
If anything, metformin’s hormonal effects would make breast enlargement less likely, not more. Breast tissue growth is driven largely by estrogen, and metformin consistently lowers estrogen levels in studies. In a large trial from the Canadian Cancer Trials Group, postmenopausal women taking metformin for six months had estradiol (the body’s main form of estrogen) roughly 25 to 30% lower than women on a placebo. A separate study using 1,500 mg daily found estradiol dropped by 38% and free testosterone fell by 29%.
Metformin also appears to reduce estrogen production directly inside breast tissue. Lab research has shown that metformin inhibits aromatase, the enzyme that converts androgens into estrogen, in the fat cells surrounding breast tissue. Less local estrogen production means less hormonal stimulation of breast cells.
Metformin and Breast Density
Breast density, which reflects the ratio of fibrous and glandular tissue to fatty tissue, is a rough proxy for how much active breast tissue someone has. A study of 74 postmenopausal women with type 2 diabetes compared breast density in those taking metformin to those who had not yet started the drug. There was no statistically significant difference between the two groups. This adds another layer of evidence that metformin does not promote breast tissue growth.
What About Women With PCOS?
Many people taking metformin have polycystic ovary syndrome, a condition involving hormonal imbalances that can affect breast tissue. A randomized controlled trial followed pregnant women with PCOS who took either metformin or a placebo and tracked breast size changes throughout pregnancy and breastfeeding. Metformin had no impact on breast size increase compared to placebo. Androgen levels during pregnancy also did not correlate with breast size changes.
Interestingly, women with PCOS who experienced no breast size increase during pregnancy tended to be more metabolically disturbed overall, with higher fasting insulin, higher triglycerides, and higher blood pressure. This suggests that the underlying metabolic condition matters more than the medication itself.
Why the Confusion Might Exist
The conditions metformin treats can themselves affect breast tissue. High insulin levels, a hallmark of type 2 diabetes and PCOS, stimulate breast cell growth independently of obesity. Animal research has demonstrated that hyperinsulinemia accelerates mammary gland development even in lean subjects: mice with severe insulin resistance but normal body weight showed increased number and size of breast tissue buds and enhanced branching compared to healthy controls.
This means someone newly diagnosed with diabetes or PCOS might notice breast changes that coincide with starting metformin but are actually driven by the insulin resistance that prompted the prescription in the first place. As metformin improves insulin sensitivity over time, it would theoretically reduce this insulin-driven stimulation rather than add to it.
Weight changes can also play a role. Metformin sometimes causes modest weight loss, but some people experience weight fluctuations, especially early in treatment. Since breasts contain a significant amount of fat tissue, any shift in body weight or fat distribution could create the perception that the medication is affecting breast size. Fluid retention from dietary changes or other medications taken alongside metformin could contribute as well.
What to Make of Anecdotal Reports
Online forums and medication review sites sometimes include reports of breast changes while taking metformin. These individual accounts are real experiences, but they don’t establish that metformin caused the change. People starting metformin are often simultaneously managing a new diagnosis, adjusting their diet, losing or gaining weight, and sometimes starting other medications. Any of these factors can influence breast tissue. The clinical evidence, across multiple studies and the FDA’s own data, consistently shows that metformin does not promote breast growth and more likely has the opposite hormonal effect.